Patent · US Active

Detection of mage-A expression

US8481700B2 · kind B2 · utility

0Cited by

5References

6Claims

0Family size

Assignees

MDxHealth SA · BE
GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Ilse Vlassenbroeck · Angleur, BE
Katja Bierau · Angleur, BE

Key dates

Filing date	Sep 17, 2008
Grant date	Jul 9, 2013
Priority date	—
Expiry date	Mar 3, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An oligonucleotide, primer or probe comprises the nucleotide sequences of any of SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 25. The oligonucleotides are useful for the detection of the methylation status of a gene, in particular the MAGE-A3 gene. The oligonucleotides are useful in primer pairs, kits and methods for determining the methylation status of the MAGE-A3 gene and for diagnosing cancer, directing therapy and selecting subjects for treatment. The primer or probe can comprise a loop or hairpin structure and can be used in real-time methylation specific PCR.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.